A process for preparing a copolymer polyol containing a reduced content of residual monomers and volatiles including the steps of: (a) providing at least one copolymer polyol containing a first initial content of residual monomers and volatiles; (b) providing at least one molecular sieve adsorbent; (c) contacting the at least one copolymer polyol with the at least one molecular sieve adsorbent for a period of time and at a temperature sufficient for the at least one molecular sieve adsorbent to adsorb at least a portion of the first initial content of residual monomers and volatiles present in the at least one copolymer polyol to reduce the first initial content of residual monomers and volatiles of the at least one copolymer polyol to form at least one copolymer polyol containing a second reduced content of residual monomers and volatiles; and (d) separating the at least one molecular sieve adsorbent containing a portion of the first initial content residual monomers and volatiles from the at least one copolymer polyol to form at least one copolymer polyol containing a second reduced content of residual monomers and volatiles.

Provided herein are integrated continuous biomanufacturing processes for producing a therapeutic protein drug substance. Also provided are systems that are capable of continuously producing a therapeutic protein drug substance.

The invention relates to a method for determining the presence of at least one distinct polypeptide in a biological sample comprising contacting the biological sample with a hydrolyzing agent, wherein the hydrolyzing agent is capable of hydrolyzing the distinct polypeptide in a sequence-specific manner such that at least one distinct peptide having a predetermined peptide measured accurate mass would result if the at least one distinct polypeptide were present in the biological sample, to obtain a hydrolyzed sample; bringing the hydrolyzed sample in contact with a substrate comprising at least one immobilized binding partner, wherein the at least one immobilized binding partner is capable of specifically binding the distinct peptide; removing the hydrolyzed sample from the substrate in a manner such that the distinct peptide would remain bound to the immobilized binding partner; contacting the substrate with an elution solution, wherein the distinct peptide would dissociate from the immobilized binding partner into the elution solution; subjecting a portion of the elution solution to liquid chromatography to segregate a plurality of molecules in the portion of the elution solution to obtain sorted molecules; determining the measured accurate mass of at least one sorted molecule present in the elution solution; and determining the presence of the at least one distinct polypeptide in the biological sample when a measured accurate mass of at least one molecule is substantially equal to the predetermined peptide measured accurate mass.

Presented herein is a ligand-assisted elution chromatography process for the separation of metal ions using a sorbent. An inorganic sorbent, titania, for example, has three types of adsorption sites: Bronsted acid (BA), Bronsted base (BB), and Lewis acid (LA). At a high pH, the BA sites can interact with the metal ions as a cation exchanger. If a ligand with COO groups is preloaded onto the sorbent, the COO groups of the ligand can adsorb onto the LA sites. The adsorbed. ligands become strong adsorption sites for the metal ions. If the Langmuir a value for metal ion adsorption is similar to that of metal ion complexation with the ligand in the mobile phase, the different metal ions can be eluted separately with an overall selectivity which is equal to the ratio of the ligand selectivity to the sorbent selectivity.

Provided herein are integrated continuous biomanufacturing processes for producing a therapeutic protein drug substance. Also provided are systems that are capable of continuously producing a therapeutic protein drug substance.

Provided herein are integrated continuous biomanufacturing processes for producing a therapeutic protein drug substance. Also provided are systems that are capable of continuously producing a therapeutic protein drug substance.

Provided herein are integrated continuous biomanufacturing processes for producing a therapeutic protein drug substance. Also provided are systems that are capable of continuously producing a therapeutic protein drug substance.

A process and circuit for direct lithium extraction (DLE) from natural or synthetic lithium-bearing solutions is disclosed, utilizing an alumina-based lithium selective adsorbent. The process circuit employs a monovalent salt wash solution, such as sodium chloride (NaCl) or potassium chloride (KCl), to displace impurities (e.g., boron, calcium, magnesium) from the adsorbent, followed by elution with water or a dilute salt solution to recover lithium. The process circuit improves the lithium-to-impurity ratio in the eluate, reduces operational and capital expenditures, and minimizes waste by recycling displaced impurities into the brine feed stream.

Parametric Differential Moving Bed named as PDMB, characterizes by obtaining target separation system's elution profile via optimized chromatography's separation parameters between selected solid sorbent and mobile phase; such generalized process employ an apparatus transforming such profile for mass production purpose, wherein disclosed apparatus bypassing imperfections observed in chromatography via new mass transfer equilibrium contact method, differential set-up between two phases, eliminating displacement zone via maintaining installed resin/adsorbent in semi-dry status thus enhancing maximum mass transfer efficiency. Through implementing aforesaid methods, disclosed apparatus further employs single stage recycle procedures to simulate moving beds operation in confined closed loop in differential protocols; which comprise multiple modules sequentially connected, yet each functions independently and simultaneously feeding feed solution, isolating at least one desired component, recycling mobile phase, concentrating multiple isolated components, regenerating adsorbent, washing and sanitizing; apparatus further integrate additional sequential unit operation installing other type solid phase material within.

There is provided a method of operating a liquid chromatography arrangement, the liquid chromatography arrangement comprising: a solvent pump arranged to flow a liquid solvent over a liquid chromatography column; a restrictor arranged to restrict the liquid solvent from leaving the liquid chromatography column; and a liquid pump arranged to provide liquid flow between the liquid chromatography column and the restrictor, the method comprising: flowing the liquid solvent through the liquid chromatography column using the solvent pump; and controlling a liquid pressure within the liquid chromatography column by providing a liquid flow between the liquid chromatography column and the restrictor using the liquid pump.